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Abstract
p53 is a master tumour repressor that participates in vast regulatory networks, including
feedback loops involving microRNAs (miRNAs) that regulate p53 and that themselves are
direct p53 transcriptional targets. We show here that a group of polycistronic miRNA-like
non-coding RNAs derived from small nucleolar RNAs (sno-miRNAs) are transcriptionally re-
pressed by p53 through their host gene, SNHG1. The most abundant of these, sno-miR-28,
directly targets the p53-stabilizing gene, TAF9B. Collectively, p53, SNHG1, sno-miR-28
and TAF9B form a regulatory loop which affects p53 stability and downstream p53-regulat-
ed pathways. In addition, SNHG1, SNORD28 and sno-miR-28 are all significantly upregu-
lated in breast tumours and the overexpression of sno-miR-28 promotes breast epithelial
cell proliferation. This research has broadened our knowledge of the crosstalk between
small non-coding RNA pathways and roles of sno-miRNAs in p53 regulation.
Introduction
The p53 tumour suppressor plays a pivotal role in the prevention of oncogenic transformation
as highlighted by the fact that over half of all tumours have mutations in TP53. Cellular insults
such as DNA damage or aberrant oncogene expression engage the p53 pathway, resulting in
rapid stabilization of p53 protein levels. Upon activation, p53 functions as a sequence-specific
transcription factor to either activate or repress the expression of target genes. The global land-
scape of p53 transcriptional regulation is vast and complex, with gene expression profiling
studies demonstrating that thousands of genes rapidly alter expression upon p53 activation [1–
3]. In addition to direct regulation, p53 also imparts a substantial amount of transcriptional
regulation through indirect mechanisms. For example, Nikulenkov et al. recently applied a
combination of ChIP-Seq (chromatin immunoprecipitation combined DNA sequencing) and
RNA-Seq (RNA Sequencing) to demonstrate that, although activation of p53 resulted in the al-
tered transcription levels of over 4500 genes, less than 10% of these genes were directly bound
by p53 [2]. Hence, a major component of the p53 transcriptional network is mediated through
various indirect effectors or non-protein coding regulators.
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MiRNAs (microRNAs) constitutes one of the largest families of trans-acting gene regula-
tors. The discovery that p53 can regulate miRNAs, coupled with the observation that many ef-
fects of p53 are indirect, suggests that they could be significant effectors in the p53
transcriptome [4]. Recently, p53 has been shown to transcriptionally activate or repress the ex-
pression of several miRNAs, including miR-17-92 cluster [5], miR-22 [6], the miR-34 family
[7–11], miR-145 [12], miR-192 family [13, 14], miR-149 [15], miR-200 family [16, 17], miR-
605 [18], miR-1204 [19], miR-509 [20], and miR-1915 [21]. Hence, by regulating a miRNA-
based network, p53 could modulate an extensive downstream transcriptome. Other families of
non-coding RNAs are also emerging as novel entities in the downstream p53 pathway, such as
long non-coding RNAs (lncRNAs) [22] and various other pol I/III transcripts including tRNA
and rRNAs [23, 24]. The extent to which these and other non-coding RNAs participate in the
p53 pathway are currently not well understood.
Herein, we have examined the ability of p53 to regulate miRNA-sized transcripts processed
from non-coding small nucleolar RNAs (snoRNAs). Our findings demonstrate a role for p53
in the repression of a family of polycistronic C/D box snoRNAs (SNORDs), of which at least
one is processed into an operative miRNA which feeds back to repress TAF9B-mediated stabi-
lization of p53 and promote cell proliferation.
Results
Identification of p53 regulated snoRNAs
Given the existing links between p53 and various non-coding RNAs, we hypothesized that p53
may also regulate snoRNAs, as snoRNAs have been linked to carcinogenesis [25, 26] To exam-
ine this, we performed snoRNA expression profiling following activation of the p53 signalling
network. This was conducted by Affymetrix gene expression profiling in two models of p53 ac-
tivation to increase the chance of identifying bona fide snoRNA targets of p53 that were not re-
stricted to specific cell type, cell origin or mode of p53 activation. These two cell-based models
of wild-type p53 activation were (i) an inducible p53 system in the p53 null H1299 cell line
(previously characterized in ref. [3]), and (ii) activation of endogenous wild-type p53 through
Nutlin-3a treatment of the WE-68 cell line (Fig 1A, S4 Table). Due to space limits, a few repre-
sentative RNA transcripts are presented in Fig 1B as examples from the microarray to indicate
the anticipated responses of these cells to p53 activation, including mRNAs, miRNAs and
snoRNAs. According to previous studies, FAS, PUMA (BBC3), CDKN1A, MDM2, RRM2B
(p53R2), BAX, CCNG1, TLR3 and MIR34A (miR-34a host gene) are upregulated upon p53 ac-
tivation [27]; ACTB (β-actin), GAPDH, PSMB4 and C1orf43 are usually stably expressed [28];
whereas E2F1 [27], CCNE2 [29], POLD1 [30], CDCA8 [31], FBXO5 [32], PLK4 [33], BRCA1
[34], CCNB1 [35] and MIRH1 (miR-17-92 host gene) [36] are directly or indirectly repressed
upon p53 activation (Fig 1B). Clustering analysis was employed to indicate the relative close-
ness of the reactive patterns how these genes respond to p53 activation in both cell lines.
In a combined analysis of both the H1299 and WE-68 cell lines using Affymetrix microar-
ray, we identified six snoRNAs that were most significantly (fold change> 1.085 or<0.915,
p<0.05) regulated by p53 between induced (H1299 treated with PonA and WE-68 treated with
Nutlin) and uninduced cells (Fig 1B). Interestingly, all six snoRNAs were clustered to MIRH1,
a polycistronic miRNA host gene of the miR-17-92 cluster that is transcriptionally repressed
by p53 [36], and this indicates probable similarity in their reactive patterns upon p53 activation
(Fig 1B). There were no snoRNAs significantly activated by p53 in either system, suggesting
that the role of p53 in the regulation of snoRNAs may be restricted to that of transcriptional re-
pression. Five of these p53-repressed snoRNAs were encoded within the same polycistronic
gene, SNHG1 (SNORD host gene 1), a precursor of a family of C/D box snoRNAs (Table 1,
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Fig 2A, S1 and S2 Tables). All eight SNHG1-encoded snoRNAs were repressed by p53, with
five reaching statistical significance (fold change> 1.085 or<0.915, p<0.05) (Table 1). Consis-
tent with this, upon activation of p53 in both H1299 andWE-68 cell lines, expression levels of
SNHG1, the SNORD host gene, was significantly reduced (Fig 1C). We next investigated if
SNHG1 was transcriptionally repressed by p53. Analysis of the promoter region of SNHG1
(~5kB upstream of initiation site of SNHG1) using p53 Scan [37] identified a putative p53 re-
sponsive element (RE). ChIP (chromatin immunoprecipitation) analysis using the H1299 p53
inducible system indicated modest but reproducible recruitment of p53 to this response ele-
ment (Fig 1D). Collectively, these data implicate SNHG1, and its processed snoRNAs, as
p53-repressed targets.
Fig 1. Identification of p53 regulated snoRNAs. (A) Wild type p53-inducible H1299 cells were treated with 2.5μg/ml of Ponasterone A (PonA) for 24 hours,
and compared with non-induced cells. WE-68 cells were treated with 10nMNutlin-3a for 16 hours, compared with non-induced cells. Western blots for p53
(and β-actin as a loading control) are shown. (B) Based on microarray profiling, a dendrogram generated by cluster analysis shows the separation of p53
uninduced cells from induced cells, and separation of representative genes activated, repressed or not significantly changed by p53. (C) SNHG1 expression
levels were determined by RT-PCR after p53 induction in H1299 andWE-68 cells. (D) ChIP assay, using the anti-p53 antibody DO-1, was performed to
determine relative p53 occupancy in p53-induced H1299 cells (+PonA). RT-PCR results show relative p53 occupation at upstream of the SNHG1 promoter,
and p53 null H1299 (-PonA) was used as a negative control. ** p<0.01 versus controls for all experiments.
doi:10.1371/journal.pone.0129190.g001
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p53 repressed snoRNAs are processed into miRNAs
In addition to their well characterized function guiding the enzymatic modification of ribo-
somal RNA, snoRNAs may also be processed into smaller miRNA-sized molecules which are
capable of binding Argonaute (AGO) and exerting miRNA-like effects. These are variously
termed sno-miRNAs or snoRNA-derived small RNAs (sdRNAs) [38–40]. Such processing is
both widespread and evolutionarily conserved [38], leading us to ask whether the products of
SNHG1 may also serve miRNA-like roles.
In order to investigate this, we analysed data from HITS-CLIP (high throughput sequencing
of crosslinked and immunoprecipitated RNA) performed in MDA-MB-231 breast cancer cells
[41]. Briefly, this technique works by the immunoprecipitation of AGO, a key component of
the miRNA processing machinery, with which bound small RNAs are also co-immunoprecipi-
tated. Associated small RNAs are then identified by deep sequencing. We found evidence of
miRNA-sized (~17-26nt) molecules derived from all characterized snoRNAs within SNHG1
(Fig 2A), with a specific small RNA mapping to the 3’ end of SNORD28 being the most abun-
dant followed by a small RNA originating from the 5’ end of SNORD25. The SNORD28- and
SNORD25- derived small RNAs were sequenced within the library 630 and 365 times respec-
tively, placing them at the level of other moderately-expressed well characterized miRNAs such
as miR-155 and miR-34a (Fig 2A). Interestingly, although a small RNA derived from
SNORD28 was the most abundant small RNA recruited to AGO, SNORD29 was by far the
most abundantly expressed SNHG1-derived snoRNA, demonstrating high processing and/or
Ago-binding selectivity (Fig 2A). In addition, the precise 5’ termini of the SNORD-28 derived
small RNA further indicates the strong specificity of RNA processing and AGO binding
(Fig 2B).
To determine if sno-miR-25 and 28 are really expressed in abundance in vivo, we measured
the endogenous expression levels of sno-miR-25 and sno-miR-28 in normal and malignant
breast tissues, and compared to miR-155 which has a moderate expression level in breast tis-
sues according to miRBase [42]. TaqMan assay showed sno-miR-28 has a higher in vivo ex-
pression level than miR-155, whereas the expression of sno-miR-25 is extremely low (S2 Fig
panel A). For this reason, we focused our research on SNORD28 and sno-miR-28. We con-
firmed the PCR efficiencies and specificities of the TaqMan assays for these RNAs, demonstrat-
ing the sno-miR-28 TaqMan assay is 16 times more specific to sno-miR-28 than to SNORD28
(S1 Fig).
Since SNORD25, SNORD28 and sno-miR-28 are all processed from SNHG1, we hypothe-
sized their expression may be affected through SNHG1 upon p53 activation. Indeed, activation
Table 1. snoRNAs repressed by p53 in H1299 andWE-68 cells.
Gene Name Accession Number p value induced/ uninduced Chromosome Location Precursor Transcript
SNORD22 NR_000008 0.021988 11q13 SNHG1
SNORD25 NR_002565 0.019725 11q13 SNHG1
SNORD26 NR_002564 0.036236 11q13 SNHG1
SNORD27 NR_002563 0.018451 11q13 SNHG1
SNORD28 NR_002562 0.02692 11q13 SNHG1
SNORA75 NR_002921 0.010118 2q37.1 NCL
Affymetrix gene expression proﬁling identiﬁed six snoRNAs that were repressed in common in H1299 and WE-68 cell lines as wild-type p53 was induced.
Statistical signiﬁcance of these snoRNAs is characterized by p-values that compare p53 induced (H1299 treated with PonA and WE-68 treated with
Nutlin) versus uninduced cells, with their host genes listed.
doi:10.1371/journal.pone.0129190.t001
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of p53 in H1299 cells resulted in significant downregulation of the expression levels of
SNORD25, SNORD28 and sno-miR-28 (Fig 2C). We also demonstrated that this regulatory
axis is not restricted to any specific p53 activation models using the HCT116 isogenic cell line
Fig 2. p53 repressed snoRNAs are processed into miRNAs. (A) SNHG1 is processed into snoRNAs including SNORD25 and SNORD28. The top panel
shows RNA deep-sequencing and HITS-CLIP (high throughput sequencing of crosslinked and immunoprecipitated RNA) results at the SNHG1 genomic loci.
Predicted stem-loop folding of SNORD25 and SNORD28 are shown. The regions marked in bold are processed into sno-miRNAs which can bind to
Argonaute proteins, which was confirmed by RNA deep-sequencing and HITS-CLIP results. The solid lines between chains represent hydrogen bonds
between adenine (A)-uracil (U) pairs and guanine (G)-cytosine (C) pairs, whereas dashed lines represent G-U pairing. (B) RNA-seq and HITS-CLIP mapping
reads across the SNORD28 region is shown indicating precise binding of sno-miR-28 to AGO (C) p53 was induced by PonA treatment in inducible H1299
cells, and the expression levels of SNORD25, SNORD28 and sno-miR-28 were determined using TaqMan assay and RT-PCR. Expression levels of
SNORD25, SNORD28 and sno-miR-28 were shown in induced or uninduced cells. (D) Isogenic HCT116 -/-p53 and HCT116 +/+p53 cell lines were used to
investigate the relation of SNHG1 and sno-miR-28 expression levels with p53. Left: p53 protein expression in the HCT116 isogenic cell lines was shown by
Western blot and β-actin was used as a loading control. Right: SNHG1 and sno-miR-28 expression was determined by RT-PCR as shown. ** p<0.01 versus
controls for all experiments.
doi:10.1371/journal.pone.0129190.g002
p53/Sno-MiRNA Feedback Regulation
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system. Indeed, HCT116 (TP53+/+) cells express significantly lower levels of SNHG1 and sno-
miR-28 than the p53 null HCT116 (TP53-/-). Taken together, these results confirm that the
SNHG1-sno-miR-28 axis is negatively regulated by p53.
sno-miR-28 functions as a miRNA
Since previous studies have demonstrated miRNA-like functions for sno-miRNAs [38–40, 43–
45], we employed a bioinformatics approach to explore potential sno-miR-28 targets. As pre-
dicted by TargetScan Custom 5.1, TAF9B (transcription initiation factor TFIID subunit 9B),
BHLHE41 (class E basic helix-loop-helix protein 41) and TGFBR2 (transforming growth factor
beta receptor II) were identified among the putative targets of sno-miR-28 (Fig 3A, S3 Fig).
Several (~10) candidate mRNAs were investigated upon overexpression or inhibition of sno-
miR-28 (data not shown), and TAF9B was associated with the greatest level of repression in re-
sponse to exogenous sno-miR-28. In addition, RNA folding analysis predicted that TAF9B has
a moderate-to-high level of hybridization energy binding to sno-miR-28 (ΔG = -21.0 kcal/mol)
(Fig 3A). [46]
TAF9B was deduced to be a target of sno-miR-28 not only by bioinformatics analysis, but
also by the inverse correlation between sno-miR-28 and TAF9B expression. Following overex-
pression of sno-miR-28, endogenous TAF9B mRNA and protein expression levels were signifi-
cantly reduced in H1299 cells (Fig 3B and 3C). To confirm that sno-miR-28 directly interacts
with TAF9B’s 3’-UTR (3’-untranslated region), we overexpressed sno-miR-28 along with a psi-
CHECK2 luciferase reporter containing the TAF9B 3’UTR fused to the 3’ end of the Renilla lu-
ciferase gene. We observed that the Renilla luciferase expression was inhibited by sno-miR-28
overexpression, and the repression was abolished by mutation of the proposed sno-miR-28 rec-
ognition site (Fig 3D). Taken together, these results demonstrate that sno-miR-28 directly me-
diates repression of TAF9B through a canonical miRNA binding site.
In order to help verify our observations are not restricted to a specific cell type, the relation
between sno-miR-28 and TAF9B was then investigated in MCF10A cells, an immortalized,
non-transformed breast epithelial cell line. Transfection of sno-miR-28 mimics downregulates
TAF9B mRNA and protein, consistent with sno-miR-28 also functioning like a canonical
miRNA in breast epithelial cells (Fig 3E and 3F). Furthermore, a Locked Nucleic Acid (anti-
sno-miR-28 LNA) was used to inhibit endogenous sno-miR-28 expression in MCF10A cells
and, consistently, TAF9B mRNA and protein expression was increased (Fig 3E and 3F). Taken
together, this indicates TAF9B is subject to regulation by the endogenous sno-miR-28.
sno-miR-28 alters p53 protein stability through TAF9B
TAF9B functions as a subunit of TFIID (transcription initiation factor II D) and TFTC
(TATA-binding Protein-free TAF-containing) complexes. It also acts as a p53 co-activator, sta-
bilizing p53 possibly by competing for Mdm2 binding [47, 48]. We therefore reasoned that via
its direct regulation of TAF9B, sno-miR-28 may indirectly regulate p53. To investigate this, we
examined p53 protein levels after sno-miR-28 overexpression in H1299 cells and found that
sno-miR-28 downregulated p53 protein but not RNA (Fig 4A and 4B), suggesting the sno-
miR-28 and TAF9B regulation of p53 may function at the protein level. In addition, sno-miR-
28 overexpression also significantly repressed multiple p53 regulated genes including
CDKN1A (p21), RRM2B, CCNG1, FAS and HDM2 in induced H1299 cells (Fig 4A and 4C).
To confirm that the sno-miR-28-TAF9B-p53 regulatory axis is not restricted to a specific
cell type or model of p53 activation, we also investigated this pathway in MCF10A cells. As
seen in H1299 cells, sno-miR-28 overexpression reduced p53 protein but not mRNA in
MCF10A cells, while inhibition of sno-miR-28 restored p53 protein levels (Fig 4B and 4D). In
p53/Sno-MiRNA Feedback Regulation
PLOS ONE | DOI:10.1371/journal.pone.0129190 June 10, 2015 6 / 20
addition, overexpression of sno-miR-28 repressed the mRNA levels of various p53 downstream
regulators including CDKN1A, HDM2, FAS, BAX and GADD45A (Fig 4E) highlighting the
prevalent influence of sno-miR-28 in p53 signalling.
Consistent with sno-miR-28 stabilizing p53 protein via its regulation of TAF9B, we found
that siRNA-mediated knockdown of TAF9B phenocopied the effect of sno-miR-28, reducing
the levels of p53 protein and CDK1A mRNA (Fig 4F–4H).
Fig 3. sno-miR-28 functions as a miRNA. (A) Proposed sno-miR-28 binding site within the TAF9B 3’UTR. The seed-recognition site is marked in bold;
hypothesized duplexes formed by the interaction of TAF9B and sno-miR-28 are illustrated, and the predicted free energy of the hybrid is indicated.
Conservation of the seed region across 4 species is also indicated. (B, C) sno-miR-28 (or negative control RNA, ncRNA) was overexpressed in H1299 cells.
TAF9BmRNA and protein levels were determined by RT-PCR andWestern blot, respectively. (D) Using a dual-luciferase reporter system, H1299 cells were
co-transfected with sno-miR-28 mimics (or negative control RNA), and psiCHECK2 luciferase reporter plasmids with either wild type (WT) or mutated TAF9B
3’-UTR (MUT) cloned at downstream of the Renilla luciferase gene (Luc). Relative luciferase activities are shown. (E, F) sno-miR-28 was either
overexpressed (mimics) or inhibited (LNA) in MCF10A cells. TAF9BmRNA levels were determined by RT-PCR (E), and protein expression was determined
byWestern blot (F). ** p<0.01 versus controls for all experiments, and β-actin was included as a loading control for all Western blots.
doi:10.1371/journal.pone.0129190.g003
p53/Sno-MiRNA Feedback Regulation
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Fig 4. sno-miR-28 alters p53 protein stability through TAF9B and forms a feed-forward loop between p53, sno-miR-28, and TAF9B. (A) Western
blots are shown to determine the protein levels of p53 and p21 after overexpression of sno-miR-28 and/or induction of p53 by Ponasterone A (PonA) in
inducible H1299 cell line, compared with cells transfected with negative control RNA (ncRNA) and/or uninduced H1299 cells. (B) p53 mRNA levels in
MCF10A and PonA-treated H1299 cells after overexpression of sno-miR-28 are shown by RT-PCR, compared with scrambled negative control (ncRNA). (C)
p53/Sno-MiRNA Feedback Regulation
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sno-miR-28 is upregulated in breast tumours and promotes breast cell
proliferation
Our findings indicate that sno-miR-28 participates in a feed forward loop with p53, whereby
p53 represses sno-miR-28 via SNHG1, whilst sno-miR-28 directly targets the TAF9B 3’UTR to
negatively regulate p53 stability (Fig 5A). The reciprocal negative association with p53 implies
sno-miR-28 might have an oncogenic role. Consistent with this, SNHG1 is upregulated in gas-
tric cancer [49]. To further investigate, in a cohort of 26 pairs of matched malignant and non-
malignant breast tissues samples, we found that SNHG1, SNORD28 and sno-miR-28 were all
significantly upregulated in breast tumours (Fig 5B). Two well-characterized oncogenic miR-
NAs, miR-21 and miR-155, that were used as positive controls were similarly upregulated (S2
Fig panel B) [50, 51]. In further agreement with an oncogenic role for sno-miR-28, we also
found that sno-miR-28 expression promoted the proliferation (Fig 5C) and colony forming ca-
pacity (Fig 5D) of MCF10A cells. Taken as a whole, these results demonstrate that sno-miR-28,
which targets TAF9B, antagonizes p53 protein levels and is capable of playing an oncogenic
role to accelerate breast cell proliferation and colony formation.
Discussion
snoRNAs are processed into miRNAs
Through the use of both microarrays and the analysis of endogenous small RNAs bound to
AGO, we discovered that a number of polycistronic snoRNAs are processed into miRNA-sized
molecules from a common host gene (SNHG1). Interestingly, we noticed from whole-cell
RNA-seq that SNORD29 is far more abundant than SNORD28, but in contrast, the sno-
miRNA derived from the SNORD28 region is the most abundantly recruited to AGO (Fig 2A).
The 5’ end of sno-miR-28 is also very precisely processed, indicating that the processing and re-
cruitment of snoRNA-derived products to AGO can be highly selective [52]. In addition, up-
regulation of SNORD28 but not SNORD25 in breast cancer tissues (Fig 5B) also indicates exis-
tence of extensive posttranscriptional regulation. These evidences strongly imply the presence
of a bonda fide RNA product, rather than random RNA degradation debris. This provides an-
other example of concomitant post-transcriptional regulation of miRNA levels by regulating
their precursors. For instance, LIN28 regulates miR-9 by inducing degradation of its precursor
[53], and blocks processing of let-7 by co-transcriptional binding [54]. In accordance with our
data, other researchers have also found smaller processed products of snoRNAs to have
miRNA-like functions. For example, snoRNA ACA45 is processed to small 20- to 25-nt-long
RNAs, one of which regulates the 3’-UTR of CDC2L6 mRNA by stably associating with AGO
proteins [44], and 11 box C/D sno-miRNAs were found to have efficient gene silencing func-
tion [39]. In addition, computational analyses has identified 84 intronic miRNAs that are en-
coded within either box C/D snoRNAs, or in precursors showing similarity to box C/D
snoRNAs [40]. Whilst functions for most of these small RNAs have not been determined, the
expanded use of deep sequencing technologies have led to the extensive profiling of small RNA
The mRNA expression levels of p53 downstream targets are shown after overexpression of sno-miR-28 (or negative control) in H1299 cells upon p53
activation. (D) sno-miR-28 (or negative control) was either expressed (mimic) or inhibited (LNA) in MCF10A cells and the protein expression of p53 was
determined byWestern blot. (E) The mRNA expression levels of p53 downstream targets are shown after overexpression of sno-miR-28 in MCF10A cell line,
compared with ncRNA. (F,G) TAF9B was knocked using an siRNA in H1299 cells compared with a negative control. Successful knockdown is shown at both
the protein (F) and mRNA (G) levels. (H) CDKN1A expression was determined by RT-PCR after TAF9B was knockdown. ** p<0.01 versus controls for all
experiments. β-actin is included as a loading control for all Western blots. “-”mark in sno-miR-28 mimic and anti-sno-miR-28 LNA experiments represent
negative control transfections using a scrambled ncRNA.
doi:10.1371/journal.pone.0129190.g004
p53/Sno-MiRNA Feedback Regulation
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fragments derived from a number of sources, including snoRNAs, tRNAs and rRNAs, and the
characterization of their dependence on Drosha or Dicer for their production [55].
sno-miR-28 is a novel member of the p53 regulatory network
While miRNAs have been known to play vital roles in the p53 pathway, our research has re-
vealed a novel miRNA regulatory pathway based on a sno-miRNA in p53 regulation. We dis-
covered that p53 transcriptionally regulates the host gene of sno-miR-28 which targets TAF9B.
TAF9B is a subunit of TFIID and TAFIIC, functioning as a stabilizer and co-activator of the
p53 protein, and has been reported to be essential for cell viability [47, 48]. In addition, TAF9B
has been previously discovered to play a role in transcriptional repression and silencing [56].
The regulation of TAF9B by sno-miR-28, and the reciprocal repression of the sno-miR host
gene by p53, suggests a role for sno-miR-28: p53 feedback in cancer, which supports recent dis-
coveries that a large number of miRNAs interact with the p53 network as an alternative mecha-
nism of the tumour-suppressor activity of p53 [5–17, 19–21, 57]. The complex regulatory loop
Fig 5. sno-miR-28 is over-expressed in breast tumours. (A) The feed-forward loop between p53, sno-
miR-28, and TAF9B is shown as proposed. (B) sno-miR-28, SNORD28, and SNORD25 expression levels
were determined using TaqMan assay in breast tumours compared with paired normal adjacent tissues,
while SNHG1 expression levels were determined by RT-PCR. In this part of figure, RNA expression levels
are shown as the ratio relative to normal tissue expression; e.g., 1 represents equal expression to normal
tissues. (C) MCF10A cell proliferation is shown after overexpression of sno-miR-28 compared with negative
control RNA (ncRNA). (D) Colony formation assay in MCF10A cells after expression of sno-miR-28 or a
negative control RNA (ncRNA). Representative images are included on the left, and relative quantitation of
the graph is on the right. ** p<0.01 and * p0.1 versus controls for all experiments.
doi:10.1371/journal.pone.0129190.g005
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involving p53, SNHG1 and TAF9B is also reminiscent of the feed-back and feed-forward mo-
tifs with which miRNAs are frequently associated [20, 58].
Furthermore, we noticed that sno-miR-28 actually represses CDKN1A mRNA more effec-
tively than merely knocking down TAF9B using a siRNA (Fig 4A, 4C, 4E and 4H), and this
might be explained by the fact that miRNAs usually have a large number of targets, many of
which have synergistic functions in the same pathway. For instance, miR-34a targets E2F3
[59], CCNE2 and CDK4 [9], CCND1 and CDK6 [60] in cell cycle regulation, and no single tar-
get can fully cover its entire function. We anticipate there will be a large number of additional
sno-miR-28 targets awaiting discovery.
sno-miR-28 is overexpressed in breast tumour samples and plays an
oncogenic role in breast cells
The regulatory role of sno-miR-28 is further confirmed by our expression profiling studies
which relate SNHG1, SNORD28 and sno-miR-28 to breast tumours. Interestingly, SNHG1 was
also reported as one of the 5 most significantly upregulated long non-coding RNAs (lncRNAs)
in gastric cancer among the 9294 lncRNAs detected [61]. The upregulation of sno-miRNA-28
and SNHG1 in tumours and its relationship to p53 parallels our understanding of other
miRNA regulatory loops that closely interact with the p53 pathway and play significant roles in
p53-mediated apoptosis and cell cycle arrest. For example, the miR-34 family mediates tumour
suppression through a positive feedback loop involving p53 and MDM4 [62]; 15 miRNAs, in-
cluding the miR-106b/93/25 cluster, miR-17-92 cluster and the miR-106a-92 cluster, are re-
pressed by p53 and involved with E2F in a feed-forward loop promoting proliferation [63];
whereas miR-192, 194 and 215 are involved in the p53-MDM2 auto-regulatory loop [64].
Whilst our research has revealed yet another feed-forward loop involving p53 and a miRNA, it
is surprising that this regulatory loop is based on a snoRNA-derived miRNA, thereby building
upon the novel regulatory roles of snoRNAs in cancer.
Collectively, this research builds on a small but growing knowledge base of small RNAs
from “unfamiliar” sources playing important biological roles. We believe more novel targets of
sno-miR-28 will be identified, and functions for more miRNAs derived from novel sources will
be explored. From this point of view, developments of knowledge in cancer regulatory net-
works and their interaction with small non-coding RNAs may eventually offer insights into
new approaches to cancer treatment.
Materials and Methods
HITS-CLIP (High throughput sequencing of crosslinked and
immunoprecipitated RNA):
MDA-MB-231 cells were suspended in cold PBS by scraping cross-linked at 254 nM using a
Stratalinker. Cell pellets were lysed (0.1% SDS, 0.5% deoxycholate, 0.5% NP-40 with protease
inhibitors, Roche, Indianapolis, IN USA) for 10 mins on ice followed by RQ1 DNAse (Pro-
mega, Madison, WI USA) at 37°C for 15 mins with shaking. RNAse A/T1 (Ambion, Grand Is-
land, NY USA) was then added for 8 minutes, prior to the addition of EDTA (30 mM). Pellets
were then spun (30,000 rpm) and the lysate subjected to immunoprecipitation for 2 h with a
pan-anti-AGO antibody (2A8) conjugated to protein-A dynabeads (Invitrogen, Grand Island,
NY USA) using bridging rabbit anti-mouse IgG (Jackson ImmunoResearch Laboratories, West
Grove, PA USA). Pellets were then successively washed (0.1% SDS, 0.5% deoxycholate, 0.5%
NP40 in 1 × PBS; 0.1% SDS, 0.5% deoxycholate, 0.5% NP40 in 5 × PBS; 50 mM Tris pH 7.5, 10
mMMgCl2, 0.5% NP40) and on-bead phosphatase treatment performed for 30 mins with
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antarctic phosphatase (New England Biolabs, NEB, Ipswich, MA USA) in the presence of
superasin RNAse inhibitor (Ambion). The 3’ RNA linker (CAGACGACGAGCGGG) was la-
beled with P32 using T4-PNK (NEB) and ligated on-bead for 1 h at 16°C with T4 RNA ligase
(Fermentas, Thermo Fisher Scientific, Pittsburgh, PA USA). Beads were then washed as previ-
ous and treated with PNK to ligate the 5’ RNA linker (AGGGAGGACGAUGCGGxxxG, with
“X” representing different nucleotides for barcoding). Beads were resuspended in 4 × LDS
Novex loading buffer with 4% B-mercaptoethanol, incubated at 70°C for 10 mins and the su-
pernatant loaded on Novex NuPAGE 4–12% Bis-Tris acrylamide gels (Bio-Rad, Hercules, CA
USA). After running, the Ago-RNA complexes were then transferred to nitrocellulose and ex-
posed to film at -80°C for 3 days. Complexes running at ~110 kDa were then excized with a
scalpel and resuspended (100 mM Tris pH 7.5, 50 mM NaCl, 10 mM EDTA, 4 mg/ml protein-
ase K) for 20 min at 37°C. The sample was incubated for an additional 20 minutes in the pres-
ence of 3.5 M urea and RNA isolated by a phenol-chloroform extraction. Samples were then
run on a 10% denaturing (1:19) polyacrylamide gel and exposed to film with an intensifying
screen at -80°C for 5 days. A thin band corresponding to the Ago-miRNA (~110 kD) was
excized, crushed and eluted at 37°C for 1 h (1M NaOAc, pH 5.2, 1 mM EDTA). RNA was pre-
cipitated overnight with ethanol, centrifuged and dried, and then resuspended in 8 μl H2O.
Next, reverse transcription primer was added and reverse transcription performed using Super-
ScriptIII (Invitrogen). After that, PCR was performed with the above primer and a reverse
primer for 25 cycles, and PCR product was run on a 10% native (1:29) polyacrylamide gel,
stained with Sybr Gold (Qiagen, Valencia, CA USA) and bands excized over a UV light box.
Following this, the DNA was precipitated using isopropanol and a final 10-cycle PCR per-
formed with the HITS-CLIP primers listed in S3 Table. Reactions were subsequently run on
2% metaphor agarose/TBE gels and bands (~115 bp) excized corresponding to the linker se-
quence + miRNA CLIP tag. Samples were finally purified using quick-spin columns (Qiagen)
and subjected to Illumina sequencing (Illuminia, San Diego, CA USA). Using an in house Perl
script, reads were filtered for average quality and for homopolymeric tracts exceeding 12 nt,
trimmed of linker sequence fragments and separated by barcode. The bowtie program [65] was
used to align resulting 17 to 30 nt reads to the human genome. The dataset has been previously
published [41] and has been deposited at the NCBI (National Center for Biotechnology Infor-
mation) SRA (Sequence Read Archive) SRP045204, BioProject PRJNA257235.
Cell lines and reagents
HCT116 (human colon cancer) and its TP53–/–derivative were supplied by B. Vogelstein [66];
MDA-MB-231 (human breast cancer) and MCF10A (human breast epithelial) cells were pur-
chased from ATCC (American Type Culture Collection, Manassas, VA USA); wild-type
p53-inducible H1299 (mentioned as H1299 below) human non-small cell lung cancer cell line
was generated as previously described [67] and was characterized in Fig 1A using Western blot;
WE-68 human Ewing's sarcoma cell line was a kind gift from Prof F. van Valen (Department
of Orthopaedic Surgery, Westfälische-Wilhelms-University, Germany) as previously described
[68]. HCT116, MDA-MB-231 and H1299 cell lines were cultured in DMEM (Sigma-Aldrich,
St. Louis, USA) and WE-68 cells were cultured on type-1 collagen-coated plates (Iwaki,
Thermo Fisher, Newport, UK) in RPMI-1640 (Sigma-Aldrich). The media above were supple-
mented with 10% (v/v) fetal calf serum and 10mmol/L HEPES. MCF10A cells were cultured in
DMEM/F12 medium (Sigma-Aldrich) supplemented with 5% horse serum, 20ng/mL EGF,
0.5μL/ml Hydrocortisone, 100ng/ml Cholera toxin, 10μg/mL Insulin. All media were supple-
mented with 2mmol/L L-Glutamine, 100 IU/mL penicillin and 100μg/ml streptomycin, and all
cell lines were cultured at 37°C in a humidified atmosphere at 5% CO2. All cell lines have been
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under regular tests every 1–2 months using MycoAlert mycoplasma detection kit (Lonza, Mel-
bourne, VIC Australia), which ensured that all cell lines being used for experiments were safe
from mycoplasma contamination.
Nutlin-3a (4-[[(4S,5R)-4,5-bis(4-chlorophenyl)-4,5-dihydro-2-[4-methoxy-2-(1-methy-
lethoxy)phenyl]-1H-imidazol-1-yl]carbonyl]-2-piperazinone) was purchased from Cayman
Biochemicals (Ann Arbor, MI USA), and Ponasterone A (PonA) was purchased from
Invitrogen.
Breast tumour and paired normal tissues
Breast tumour and paired normal adjacent tissue samples were obtained from 26 breast cancer
patients who have received surgery at the Royal Adelaide Hospital (Adelaide, Australia) be-
tween 2003 and 2011. Samples were stored in RNAlater solution (Ambion) for RNA stabiliza-
tion before RNA extraction using miRNeasy kit (Qiagen) following the manufacturer’s
protocol. RNA concentration was determined using a ND-1000 NanoDrop spectrometer
(Thermo Scientific, Wilmington, DE USA). This research has been approved by the Institu-
tional Review Boards of the University of Adelaide and SA Pathology. All samples were gath-
ered according to the institutional review board-approved protocol and the written informed
consent from each patient. Relevant clinical data was retrieved from patients’ records including
human epidermal growth factor 2 (HER2), estrogen receptor (ER), progesterone receptor (PR)
and proliferation index (MIB-1) status.
miRNA overexpression and inhibition
For miRNA overexpression studies, approximately 3 × 105 cells/well were seeded in 6-well
plates (for RT-PCR (real-time quantitative PCR) or Western blot) and 1 x 105 cells/well were
seeded in 24-well plates (for luciferase assay, proliferation assay and colony formation). Trans-
fections were done 24 hours post-seeding with 50 nM Genepharma miRNA mimics (Gene-
pharma, Shanghai, China) or negative control RNA (ncRNA) (Genepharma) using
Lipofectamine RNAiMAX reagent (Invitrogen) following the manufacturer’s instructions. The
cells were harvested 72 hours post-transfection for RT-PCR, Western blot, or luciferase assay.
For miRNA inhibition studies, approximately 3 × 105 cells/well were seeded in six-well
plates. The first transfection was done 24 hours post-seeding with 50 nMmiRVana miRNA in-
hibitor (Ambion) or 50 nMmiRVana miRNA inhibitor negative control RNA (ncRNA)
(Ambion) using Lipofectamine RNAiMAX reagent (Invitrogen) following the manufacturer’s
instructions. Cells were harvested 72 hours post-transfection for further experiments.
RNA interference
RNA interference of TAF9B was performed using siTAF9B (AGUAUGAACCAAGG-
GUUAUAA) (GenePharma). The transfection procedure using Lipofectamine RNAiMAX re-
agent (Invitrogen) is the same as described above for miRNA overexpression and inhibition.
Luciferase Assay
For the luciferase assay, we cloned the TAF9B 3’-UTR (WT) downstream of the Renilla lucifer-
ase gene in the psiCHECK2 dual-luciferase vector (Promega) (for primers, see S3 Table). The
Firefly luciferase gene (which is expressed from the same vector from an HSV-TK promoter)
was used as an internal reference. For the mutated TAF9B 3’-UTR (MUT) construct, a 24 bp
mutation was introduced at the proposed sno-miR-28 binding site (CTTTCAGAATTG
TAAAATGCTATA to GAATTCAAAAAAAAAAAAAAAAAA) (Fig 3D, left panel) (for
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primers, see S3 Table). Approximately 1 × 105 H1299 cells/well in 24-well plates. After 24
hours, in each well we co-transfected 0.4 ng/μL of either WT or MUT luciferase constructs
with 8.33 nM of either sno-miR-28 mimics (Genepharma) or negative control RNA (ncRNA)
(Genepharma), using Lipofectamine 2000 (Invitrogen) following the manufacturer’s instruc-
tions. Cells were harvested 72 hours post-transfection, and Renilla and Firefly luminescence
were measured by a GloMax 20/20 Luminometer (Promega) following the manufacturer’s in-
structions. A ratio of Renilla/Firefly luminescence intensity was used to indicate the relative lu-
ciferase expression activity.
Western blot and ChIP analysis
Cells were rinsed with PBS and lysed in lysis buffer (50 mmol/L Tris-HCl, pH 7.5, 250 mmol/L
NaCl, 1% Triton X-100 and 1x protease inhibitors (Roche, South San Francisco, CA)) on ice
for 30 min. Insoluble components of cell lysates were removed by centrifugation for 10 min at
4°C, 12,000 g, and protein concentration was measured using a bicinchoninic acid protein
assay kit (Pierce, Thermo Scientific, Radnor, PA USA). Protein extracts were resolved using
SDS PAGE electrophoresis on 10% polyacrylamide gels and electrotransferred to Hybond- C
Extra nitrocellulose membranes (GE Healthcare Life Sciences, Pittsburgh, PA USA).
For quantification, p53 protein was probed by mouse monoclonal p53 antibody (DO-1)
(Santa Cruz, 1:1000) (Dallas, TX USA); TAF9B was probed by rabbit monoclonal TAF9B anti-
body (Abcam, at 1:1000) (Cambridge, MA USA); p21 was probed by mouse monoclonal
p21WAF1 Ab-3 antibody (Thermo Scientific, 1:250); Equal loading was confirmed by blotting of
β-actin antibody (Sigma-Aldrich, 1:2000). Chemiluminescent detection of protein was done
using appropriate secondary antibodies conjugated with horseradish peroxidise (GE Health-
care) and the enhanced chemiluminescence kit (GE Healthcare) according to the
manufacturer's instructions.
ChIP analysis was performed as previously described [57] using mouse p53 antibody (DO-
1) (Santa Cruz). The uninduced H1299 cells were used as a p53-null control. Levels of specific
promoter DNAs were determined by real-time PCR using specific primers. A negative genomic
region which does not contain any p53 responsive element was used as a negative control, and
a pair of primers targeting the p53 recognition site of CDKN1A was used as a positive control
(S3 Table). Data presented is the mean of three independent biological replicates.
RNA extraction and Real-time PCR
RNA (>250nt) extraction from cells was performed using the RNAeasy mini kit (Qiagen)
using on-column RNase-free DNase digestion according to the manufacturer’s instructions.
After extraction, RNA concentration was measured using a ND-1000 NanoDrop spectrometer
(Thermo Scientific). Thereafter, 1μg of total RNA was reverse-transcribed into cDNA using
Moloney Murine Leukaemia Virus (M-MLV) Reverse Transcriptase (Promega) with random
6’mer primers or oligo-dT primer (Promega) under the following the manufacturer’s instruc-
tions. Real-time PCR reaction was performed on a CFX Connect Real-Time PCR Detection
System (Bio-Rad) using iTaq Universal SYBR Green Supermix (Bio-Rad). The RT-PCR pro-
gram was: 95°C for 3min, then start cycles consisting 95°C for 10s and 57/60/61°C for 60s (de-
pending on the primers used) for 40 cycles. After the reactions were complete, the CT values
were determined using automated threshold settings. In this study, RNA (>250bp) expression
was normalized to PSMB4 (S3 Table).
Small RNAs (including miRNAs and sno-miRNAs) were extracted using the miRNeasy
mini kit (Qiagen) following the manufacturer’s instructions. After extraction, total RNA con-
centration was determined using a ND-1000 NanoDrop spectrometer (Thermo Scientific). For
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quantification of small RNAs, TaqMan gene expression assays were obtained from Applied
Biosystems (Grand Island, NY USA), including TaqMan assays for miR-21, miR-155, miR-16,
miR-24 and U6 snRNA, and Custom TaqMan assays for SNORD25, SNORD28, sno-miR-25,
sno-miR-28. Reverse transcription was performed using a TaqMan MicroRNA Reverse Tran-
scription Kit (Applied Biosystems) and specific Reverse Transcription stem-loop primers pro-
vided in the TaqMan RNA assays following the manufacturer’s instructions. Real-time PCR
reaction was performed on a Rotor Gene 6000 Real-Time PCRMachine (Qiagen) using specific
TaqMan RNA assays following the manufacturer’s instructions. Small RNA expression in cell
samples was normalized to U6 snRNA, whereas small RNA expression in tissue samples was
normalized to averaged relative expression level of a group of pooled normalizers: miR-24,
U44, U48 and U6.
To determine the endogenous expression levels of sno-miRNAs in breast tissues, we per-
formed absolute quantitation of sno-miR-28 and sno-miR-28 in breast tissues, and miR-155
was used as a positive control. Synthesized sno-miR-28 and miR-155 miRNA oligos were pre-
pared at a gradient of known concentrations at 4 nM, 0.4 nM, 0.04 nM and 0.004 nM, while
synthesized sno-miR-25 was prepared at 4 pM, 0.4 pM, 0.04 pM and 0.004 pM to match its
lower expression in tissues. RT-PCR was performed subsequently and CT values were plotted
to log10 of the miRNA concentrations respectively to create a standard curve (S1 Fig panels A,
B, C), which was used to determine the endogenous expression levels of sno-miR-28, sno-miR-
25 and miR-155 in 26 breast tumour tissues and paired-matching non-malignant breast tissues
(S2 Fig panel A).
Since sno-miR-28 is processed from a region of SNORD28 near its 3’ end (Fig 2A), there is
possibility of mispriming in stem-loop PCR. To make sure that our sno-miRNA expression
data is not a result of mispriming, we conducted sno-miR-28 TaqMan RT-PCR using 2nM of
synthesized SNORD28 mimics or sno-miR-28 mimics as templates.
Cell proliferation assay and colony formation
MCF10A breast cells were plated in 24-well plates at about 1 x 105 cells/well and transfected ac-
cording to the procedure described above as miRNA overexpression. At 72 hours post-trans-
fection, the cells were harvested for proliferation or colony formation assays.
For proliferation assay, the cells were re-plated in 96-well plates in 5 replicate wells for each
experimental group (i.e., ncRNA, sno-miR-28 mimics) at 2000 cells/well and were incubated in
normal culture conditions for 6 hours to attach. After that, these cells were processed at 0, 24,
48, 72, 96 hour time points using the CellTiter-Glo Luminescent Cell Viability Assay Kit (Pro-
mega) according to the manufacturer’s instructions. Fluorescence was measured using a
LUMIstar Galaxy luminometer (BMG Labtech). The fluorescence readings in each experimen-
tal group were normalized against the 0 hour point.
For colony formation, cells were re-plated in 6-well plates at 500/1000/2000 cells/well and
were incubated in normal culturing conditions for 7 days. Then the cells were fixed in metha-
nol for 15 minutes, and stained for 1 hour in 1:20 Giemsa Stain, Modified Solution (Sigma-Al-
drich). Afterwards, colonies were photographed by a digital camera and counted.
Microarray profiling
An Affymetrix Human Gene 1.0 ST array containing 234 annotated snoRNAs (Affymetrix,
Santa Clara, CA USA) was used to identify snoRNAs that were differentially expressed follow-
ing the manufacturer’s instructions as previously described [57, 69]. “Fold change” refers to the
ratio of expression in induced (H1299 treated with PonA and WE-68 treated with Nutlin) ver-
sus uninduced cells. Statistical criteria for microarray: fold change> 1.085 or<0.915, p<0.05.
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Statistical analysis
Results are given as mean of at least three independent experiments ± standard deviation. Stu-
dent’s t-test was performed using replicate values to indicate significance. Values of p<0.05
were considered statistically significant (as labelled with  in figures), while values of p<0.1
were indicated by .
Supporting Information
S1 Fig. Characterization of snoRNA and sno-miRNA RT-PCR. (A, B, C) Standard curves
were shown for absolute quantitation of endogenous sno-miR-28, sno-miR-25 using custom
TaqMan assays with miR-155 included as a positive control. Synthesized sno-miR-28 and
miR-155 were prepared at a series of known concentrations at 4nM, 0.4nM, 0.04nM, and 0.004
nM, while synthesized sno-miR-25 was prepared at 4pM, 0.4pM, 0.04pM, and 0.004 pM to
match its low endogenous expression detected in tissues. RT-PCR was performed subsequently
and CT values were plotted to log10 of the miRNA concentrations. The point representing
0.004pM of sno-miR-25 was not plotted because no CT value was detectable at this concentra-
tion. (D) sno-miR-28 TaqMan RT-PCR was performed using synthesized SNORD28 or sno-
miR-28 as templates. RT-PCR readings are shown to evaluate the specificity of the sno-miR-28
TaqMan assay.
(TIF)
S2 Fig. Evaluation of endogenous expression of miRNAs. (A) The standard curves in S1 Fig
were used to define a standard curve for the absolute expression of miR-155, sno-miR-28 and
sno-miR-25 in 26 breast tumour tissues and paired normal adjacent breast tissues using Taq-
Man assay and RT-PCR. The average expression levels of sno-miR-28, miR-155, and sno-miR-
25 are shown in millions of molecules per nanogram (ng) of total RNA. (B) miR-21 and miR-
155 expression was determined as positive controls using Taqman assay and RT-PCR in breast
tumours compared with paired normal tissue.
(TIF)
S3 Fig. Hybridization of sno-miR-28 binding to BHLHE41 (A) and TGFBR2 (B). Bioinfor-
matics analysis showed the binding of sno-miR-28 to BHLHE41 and TGFBR2 3’-UTR in a sim-
ilar manner as other miRNAs binding to their targets. The schematic graphs are made to show
the proposed binding sites for sno-miR-28. The seed-recognizing sites are marked in red; hy-
pothesized duplexes formed by the interaction of the binding sites of the 3’-UTR of TAF9B and
sno-miR-28 are illustrated, and the predicted free energy of the hybrids were indicated. The
solid lines between two chains represent hydrogen bonds between adenine (A)-uracil (U) pairs
and guanine (G)-cytosine (C) pairs, whereas dashed lines represent G-U pairings.
(TIF)
S1 Table. snoRNAs repressed by p53 in H1299 cells. As wild-type p53 was induced in H1299
cells, Affymetrix gene expression profiling identified a list of snoRNAs that were repressed.
These snoRNAs are listed with their host genes.
(PDF)
S2 Table. snoRNAs repressed by p53 in WE-68 cells.When wild-type p53 was induced in
WE-68 cells, Affymetrix gene expression profiling identified a list of snoRNAs that were re-
pressed. These snoRNAs are shown with their host genes.
(PDF)
S3 Table. Primer list. Primers used in this study are listed by targets and usage.
(DOC)
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S4 Table. Significant genes in the microarray. All genes significantly regulated in both H1299
andWE-68 cell lines upon p53 activation are listed with fold change and p values. “Fold
change” refers to the ratio of expression in induced (H1299 treated with PonA and WE-68
treated with Nutlin) versus uninduced cells. Statistical criteria for microarray: fold
change> 1.085 or<0.915, p<0.05.
(XLSX)
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